Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sage May Be Forced To Simplify Brexanolone Dosing Regimen

Executive Summary

Advisory committee members warned of dosing errors and other potential problems with the titration/taper regimen used in the clinical trials, arguing a simpler dosing schedule also could increase patient access.

Related Content

Zulresso Postmarket Commitment Hints At Easier Dosing In Postpartum Depression
Sage Gets More Time For Zulresso Launch Preparations With Delay Of US FDA Approval
Sage's Brexanolone Could Be Transformative, But Only In Controlled Settings, US FDA Panel Says
Sage's Postpartum Depression Drug Brexanolone Faces Loss-Of-Consciousness Questions


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts